Related Experiment Video
Updated: Aug 19, 2026
Pancreatic Duct Infusion: An Effective and Selective Method of Drug and Viral Delivery
Published on: September 30, 2021
Immunobiotherapy directed against mutated and aberrantly expressed gene products in pancreas cancer
Janet M D Plate1, Jules E Harris
1Division of Hematology and Oncology, Rush University Medical Center, Chicago, Illinois 60612, USA. jplate@rush.edu
Abstract:
Genetic alterations are responsible for the development of cancer in ductal cells of the pancreas. These genetic changes result in abnormal molecular expression of proteins that are involved in cell proliferation, cell cycle control and adhesion. Some of the genetic mutations result in aberrant proteins that can be recognized as novel or foreign by cells of innate and adaptive immune systems. These are appropriate targets for therapeutic intervention which may involve immunobiologic approaches. These approaches may be less effective because of immune escape mechanisms developed by tumor cells within the microenvironment of the tumor mass. Immunobiotherapy intervention of pancreas cancer must circumvent these obstacles and integrate effective immunotherapy with molecularly targeted approaches to pancreas cancer intervention.
Insights
Pancreatic ductal cell cancers arise from genetic mutations causing abnormal protein expression. Immunotherapy can target these aberrant proteins, but tumor cells develop immune escape mechanisms, necessitating combined therapeutic strategies.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Pancreatic cancer originates from genetic alterations in ductal cells.
- These alterations lead to abnormal protein expression affecting cell proliferation, cycle control, and adhesion.
- Aberrant proteins can be recognized by the immune system, presenting therapeutic targets.
Purpose of the Study:
- To investigate the potential of immunobiologic approaches for pancreatic cancer intervention.
- To address the challenges posed by immune escape mechanisms in pancreatic tumors.
- To explore the integration of immunotherapy with molecularly targeted therapies.
Main Methods:
- Analysis of genetic alterations in pancreatic ductal cells.
- Identification of aberrant proteins as potential immunotherapeutic targets.
- Evaluation of tumor microenvironment's role in immune evasion.
Main Results:
- Genetic mutations in pancreatic cancer induce abnormal protein expression.
- These aberrant proteins can trigger immune responses.
- Tumor cells employ immune escape mechanisms within the tumor microenvironment.
Conclusions:
- Immunotherapy holds promise for pancreatic cancer treatment by targeting aberrant proteins.
- Overcoming immune escape mechanisms is crucial for effective immunobiotherapy.
- A combination of immunotherapy and molecularly targeted approaches is essential for successful pancreatic cancer intervention.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...